Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.63 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.63 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | SYK | P43405 | 2/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84027 | 0.85 | IGF1R (0.59) | EGFRPIK3CGPIK3CAPIK3CBIGF1R | |
| SCHEMBL91589 | 0.82 | EGFR (0.74) | EGFRPIK3CGPIK3CAPIK3CBKCNH3 | |
| SCHEMBL1377802 | 0.82 | EGFR (1.00) | EGFRPIK3CGPIK3CAPIK3CBIGF1R | |
| SCHEMBL15181344 | 0.82 | PLK1 (0.49) | EGFRPIK3CGPIK3CAPIK3CBSYK | |
| SCHEMBL2284267 | 0.81 | EGFR (0.72) | EGFRPIK3CGPIK3CAPIK3CBKCNH3 | |
| SCHEMBL84004 | 0.81 | CDK2 (0.54) | EGFRPIK3CGPIK3CASYKKDR | |
| SCHEMBL84435 | 0.81 | CDK2 (0.47) | EGFRPIK3CGPIK3CAPIK3CBIGF1R | |
| Hydrochloric Acid SCHEMBL12813301 | 0.80 | EGFR (0.71) | EGFRPIK3CGPIK3CAPIK3CBKCNH3 | |
| SCHEMBL31046394 | 0.78 | EGFR (0.92) | EGFRPIK3CGPIK3CAPIK3CBIGF1R | |
| SCHEMBL27116598 | 0.78 | PIK3CG (0.83) | EGFRPIK3CGPIK3CAPIK3CBSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | EGFR 197/4885PIK3CG 222/4885PIK3CA 30/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | EGFR 782/4885PIK3CG 124/4885PIK3CA 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.